JP2024161509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024161509A5 JP2024161509A5 JP2024136804A JP2024136804A JP2024161509A5 JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5 JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5
- Authority
- JP
- Japan
- Prior art keywords
- multivalent antibody
- linker comprises
- hinge sequence
- antibody according
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650467P | 2018-03-30 | 2018-03-30 | |
| US62/650,467 | 2018-03-30 | ||
| JP2021502692A JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
| PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Division JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024161509A JP2024161509A (ja) | 2024-11-19 |
| JP2024161509A5 true JP2024161509A5 (enExample) | 2025-04-02 |
Family
ID=66349617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
| JP2024136804A Pending JP2024161509A (ja) | 2018-03-30 | 2024-08-16 | 多価抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11952424B2 (enExample) |
| EP (1) | EP3774885A2 (enExample) |
| JP (2) | JP7603578B2 (enExample) |
| KR (1) | KR20200139189A (enExample) |
| CN (1) | CN111936514A (enExample) |
| AR (1) | AR115320A1 (enExample) |
| AU (2) | AU2019243665B2 (enExample) |
| BR (1) | BR112020019795A2 (enExample) |
| CA (1) | CA3094318A1 (enExample) |
| EA (1) | EA202091871A1 (enExample) |
| IL (1) | IL277672A (enExample) |
| MA (1) | MA52212A (enExample) |
| MX (1) | MX2020010267A (enExample) |
| NZ (1) | NZ767923A (enExample) |
| PH (1) | PH12020551504A1 (enExample) |
| SG (1) | SG11202009036YA (enExample) |
| TW (1) | TW202003569A (enExample) |
| WO (1) | WO2019190327A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7603578B2 (ja) | 2018-03-30 | 2024-12-20 | メルス ナムローゼ フェンノートシャップ | 多価抗体 |
| MA54643A (fr) | 2018-12-31 | 2021-11-10 | Merus Nv | Multimères multivalents tronqués |
| EA202191448A1 (ru) | 2018-12-31 | 2021-11-19 | Мерус Н.В. | Смешанные связывающие домены |
| TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| CN114605546A (zh) * | 2019-03-29 | 2022-06-10 | 美勒斯公司 | Cd3结合分子 |
| NZ782091A (en) | 2019-05-09 | 2025-08-29 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
| JP7633259B2 (ja) | 2019-12-24 | 2025-02-19 | メルス ナムローゼ フェンノートシャップ | ＴＧＦ－βＲＩＩ結合タンパク質 |
| CN114945596A (zh) * | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| JP2023526630A (ja) | 2020-05-21 | 2023-06-22 | メルス ナムローゼ フェンノートシャップ | Ｉｇ様分子の製造のための方法および手段 |
| US11692217B2 (en) * | 2020-11-11 | 2023-07-04 | Nautilus Subsidiary, Inc. | Affinity reagents having enhanced binding and detection characteristics |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| MX2024010773A (es) * | 2022-03-03 | 2024-09-10 | Pfizer | Anticuerpos multiespecificos y usos de estos. |
| US20230383012A1 (en) * | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
| WO2024144396A1 (en) | 2022-12-27 | 2024-07-04 | Merus N.V. | Method for generating bispecific proteins |
| AU2023415595A1 (en) * | 2022-12-30 | 2025-07-17 | Merus N.V. | Promiscuous cd3 binding molecules |
| CN117946245B (zh) * | 2023-02-23 | 2024-08-02 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2024206568A2 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025230409A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1309705B1 (en) * | 2000-07-25 | 2012-02-15 | Immunomedics Inc. | Multivalent target binding protein |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2556747B1 (en) | 2008-06-27 | 2020-12-02 | Merus N.V. | Antibody producing transgenic mice |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| AU2010249470B2 (en) | 2009-05-20 | 2015-06-25 | Novimmune S.A. | Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011084255A2 (en) | 2009-12-17 | 2011-07-14 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| JP2015527869A (ja) * | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムＦｃ二重特異性抗体 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2870821C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| LT2900694T (lt) * | 2012-09-27 | 2018-11-12 | Merus N.V. | Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai |
| EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| MX2015010843A (es) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| DK3089994T3 (da) * | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| JP6967853B2 (ja) | 2014-02-28 | 2021-11-17 | メルス ナムローゼ フェンノートシャップ | ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体 |
| WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US20170306044A1 (en) | 2014-10-09 | 2017-10-26 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| ES2850325T3 (es) | 2014-10-09 | 2021-08-27 | Engmab Sarl | Anticuerpos biespecíficos contra CD3epsilon y ROR1 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| PL3115376T3 (pl) * | 2015-07-10 | 2019-01-31 | Merus N.V. | Ludzkie przeciwciało wiążące cd3 |
| HRP20200390T1 (hr) | 2015-08-03 | 2020-06-12 | Engmab Sàrl | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| SG11201803359VA (en) * | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
| CA3022143A1 (en) | 2016-03-25 | 2017-09-28 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| BR112018071276A2 (pt) * | 2016-04-27 | 2019-02-12 | Pfizer Inc. | anticorpos anti-il-33, composições, métodos e usos dos mesmos |
| JP7258556B2 (ja) | 2016-04-28 | 2023-04-17 | ビオミューネクス・ファルマシューティカル | Ｅｇｆｒ及びｈｅｒ２をターゲティングする二重特異性抗体 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP3515951B1 (en) | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| IL266424B2 (en) | 2016-11-02 | 2023-09-01 | Engmab Sarl | A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma |
| US11780925B2 (en) * | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
| CA3058341A1 (en) * | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| IL313753A (en) * | 2017-07-06 | 2024-08-01 | Merus Nv | Bispecific anti pd1-anti tim3 antibodies |
| CA3068929A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| AU2018297061B2 (en) * | 2017-07-06 | 2021-05-06 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
| SG11202001050PA (en) * | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| EP3717008A1 (en) * | 2017-12-01 | 2020-10-07 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| JP7603578B2 (ja) | 2018-03-30 | 2024-12-20 | メルス ナムローゼ フェンノートシャップ | 多価抗体 |
| EA202191448A1 (ru) * | 2018-12-31 | 2021-11-19 | Мерус Н.В. | Смешанные связывающие домены |
| NZ782091A (en) * | 2019-05-09 | 2025-08-29 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
| PH12022551291A1 (en) * | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| CN114945596A (zh) * | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
-
2019
- 2019-03-29 JP JP2021502692A patent/JP7603578B2/ja active Active
- 2019-03-29 NZ NZ767923A patent/NZ767923A/en unknown
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko not_active Ceased
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en not_active Ceased
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
-
2024
- 2024-02-13 US US18/440,607 patent/US20240352127A1/en active Pending
- 2024-02-13 US US18/440,582 patent/US20240360217A1/en active Pending
- 2024-08-16 JP JP2024136804A patent/JP2024161509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024161509A5 (enExample) | ||
| Hassanzadeh-Ghassabeh et al. | Nanobodies and their potential applications | |
| JP6753945B2 (ja) | 抗人ｐｄ−ｌ１人源化単クローン抗体及び応用 | |
| Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
| Schuster | Bispecific antibodies for the treatment of lymphomas: Promises and challenges | |
| JP2024150445A5 (enExample) | ||
| CN113677359A (zh) | Cd25抗体 | |
| CN109219619A (zh) | 抗lag-3抗体 | |
| Guimaraes Koch et al. | International nonproprietary names for monoclonal antibodies: an evolving nomenclature system | |
| JPH03500005A (ja) | 組換えｄｎａタンパクの製造方法 | |
| CA2146854A1 (en) | Recombinant specific binding protein | |
| JP2006515503A5 (enExample) | ||
| AU680685B2 (en) | Retargeting antibodies | |
| KR960704575A (ko) | 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance) | |
| Singh et al. | Antibodies: Monoclonal and polyclonal | |
| TW202122576A (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2020007318A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2024514109A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JPH01501201A (ja) | 抗体 | |
| Silverstein | Labeled antigens and antibodies: the evolution of magic markers and magic bullets | |
| AU2022273136A1 (en) | Binding molecule against dll3 and use thereof | |
| Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| CN107840885A (zh) | Gm‑csf抗体及其用途 |